Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD7 CAR-T cells injection
- Development stage
- Unknown
- Lead developer
- Zhejiang University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**CD7 CAR-T cells injection** is an investigational CD7-directed chimeric antigen receptor T-cell therapy being studied by Zhejiang University as part of a sequential treatment strategy followed by allogeneic hematopoietic stem-cell transplantation. In the registered early-phase study for non-malignant blood and immune-system diseases, the product is intended for patients with hereditary bone-marrow-failure syndromes, congenital immunodeficiency, and transfusion-dependent hemoglobinopathies who have an indication for allogeneic transplantation. The CAR-T cells recognize CD7-expressing T cells, producing CD7-positive T-cell depletion before transplantation; allo-HSCT is a separate procedural component of the clinical strategy rather than an ingredient of the cell product.
- Other names
- CD7 CAR-T cellsCD-7 CAR-T cellsCD 7 CAR-T cellsCD7-targeted CAR-T cellsCD-7-targeted CAR-T cellsCD 7-targeted CAR-T cells
02
Targets
CD7 (CD7 antigen)
Beyond the preview
Go deeper on CD7 CAR-T cells injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD7 CAR-T cells injection.